Price$32.04-1.20 (-3.60%)
01:30 PM07:15 PM
News · 26 weeks84+9%
2026-04-192026-10-11
Mix4190d
- Insider21(51%)
- Other12(29%)
- SEC Filings6(15%)
- Earnings2(5%)
Latest news
25 items- PRCastle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026FRIENDSWOOD, Texas, Oct. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2026, after the close of market on Thursday, Nov. 5, 2026.Company management will host a webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.Webcast DetailsThe live webcast can be accessed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=tHS7IFft, or via the webcast link on the Investor Relations page of the Company's website: https://ir.castlebiosciences.com/. Pleas
- INSIDERSEC Form 4 filed by Castle Biosciences Inc.4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- PRACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's EsophagusStudies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings aloneFRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that new data from three studies evaluating its TissueCypher Barrett's Esophagus (BE) test will be presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and Postgraduate Course, taking place Oct. 9-14 in Nashville, Tennessee. The studies include two case reports and one multi-center study highlighting how TissueCypher can provide a
- INSIDERSEC Form 4 filed by Castle Biosciences Inc.4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- SECSEC Form 144 filed by Castle Biosciences Inc.144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- INSIDERSEC Form 4 filed by Castle Biosciences Inc.4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERChief Commercial Officer Juvenal Tobin W sold $232,128 worth of shares (6,577 units at $35.29) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 52,007 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- PRLate-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical ManagementData show patients with low-risk DecisionDx-Melanoma i31-SLNB results had sentinel lymph node (SLN) positivity below 5% when biopsied, and eligible patients who avoided SLNB had five-year recurrence-free survival (RFS) of 99.6% Separate ePoster shows DecisionDx-Melanoma identifies early-stage, transected melanomas with recurrence risk similar to that seen in stage IIB disease, supporting closer surveillance when staging is uncertainFRIENDSWOOD, Texas, Sept. 30, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data on DecisionDx-Melanoma at the European Academy of Dermatology and Venereo
- PRNew Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's EsophagusFRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study showing that its TissueCypher® Barrett's Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett's esophagus (NDBE). In the study, clinicians changed their management recommendations 90% of the time after receiving TissueCypher results, including escalating management for all patients with intermediate- or high-risk results and de-escalating management for 84% of those with low-risk results.The study, titled "The Tissue Systems Pathology
- PRNew Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacyAmong patients surveyed in the study, 94% of those open to a new systemic therapy expressed interest in molecular testing to help identify a more effective treatmentFRIENDSWOOD, Texas, Sept. 24, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study highlighting the challenges patients with atopic dermatitis (AD) experience in achieving their treatment goals and strong patient interest in molecular testing to help guide systemic therapy selec
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 8,580 shares at a strike of $2.39 and sold $512,202 worth of shares (14,496 units at $35.33) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- PRCastle Biosciences to Open New Laboratory Facility in ScottsdaleNew 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growthFRIENDSWOOD, Texas, Sept. 22, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the opening of its new laboratory and office facility in Scottsdale, Arizona. The Company will commemorate the milestone with a grand opening celebration at the new facility, located at 8667 E. Hartford Drive, on Tuesday, October 6, 2026, at 3:30 p.m. Mountain Standard Time.Government officials and community leaders are expected to attend, underscoring the significance of Castle'
- INSIDERChief Commercial Officer Juvenal Tobin W sold $222,621 worth of shares (6,600 units at $33.73) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 58,584 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 8,584 shares at a strike of $2.39 and sold $464,870 worth of shares (14,518 units at $32.02) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- PRNew Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's EsophagusDecision modeling study shows use of TissueCypher can nearly double appropriate escalation of care for patients with non-dysplastic Barrett's esophagus who later progress to cancer, while substantially reducing overuse of procedures in patients who do not progressFRIENDSWOOD, Texas, Sept. 15, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new decision modeling study showing that the TissueCypher® Barrett's Esophagus test (TSP-9) can help better align Barrett's esophagus (BE) management with a patient's individual risk of progression to high-grade dysplasia (HGD) or
- SECSEC Form 144 filed by Castle Biosciences Inc.144 - CASTLE BIOSCIENCES INC (0001447362) (Subject)
- PRJAAD Publication Shows Improved Performance of DecisionDx®-SCCDecisionDx-SCC shows enhanced performance with the integration of select clinicopathologic risk factors, providing a more precise result to support risk-aligned patient managementDecisionDx-SCC's Class 1A (low risk) result demonstrated a 97.3% negative predictive value, supporting confidence in de-escalation decisions, while its Class 2B (highest risk) result identified patients most likely to benefit from adjuvant radiation therapyFRIENDSWOOD, Texas, Sept. 9, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a multi-center study in the Journal of the American Academy of
- PRSciBase receives additional order from Castle Biosciences, advancing the collaborationSTOCKHOLM, Sept. 8, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, today announces that it has received an additional order for an acceleration of the current, ongoing clinical study and preparations for a second clinical study under the collaboration with Castle Biosciences. The order consists of both the portable Nevisense Go pen device and electrodes to a value of around $0.6 million or approximately MSEK 5. In 2025, SciBase entered into a collaboration and license agreement with Castle Biosciences (NASDAQ:CSTL), a US-based leader in molecular diagnostics. The first study under the collaboration pr
- INSIDERChief Operating Officer Oelschlager Kristen M exercised 4,152 shares at a strike of $3.38 and sold $138,643 worth of shares (4,152 units at $33.39) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERChief Commercial Officer Juvenal Tobin W sold $56,761 worth of shares (1,730 units at $32.81) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 65,184 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERPres. & Chief Exec. Officer Maetzold Derek J exercised 12,428 shares at a strike of $2.39 and sold $616,134 worth of shares (18,560 units at $33.20) as part of a pre-agreed trading plan (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERChief Commercial Officer Juvenal Tobin W sold $317,112 worth of shares (9,050 units at $35.04) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 66,914 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- INSIDERChief Operating Officer Oelschlager Kristen M sold $837,865 worth of shares (24,602 units at $34.06) (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
- PRCastle Biosciences to Participate in Upcoming Investor ConferencesFRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2026 Global Healthcare Conference on Tuesday, Sept. 15, 2026, at 10:50 a.m. Eastern time.A live audio webcast of the Company's presentation will be available by visiting Castle Biosciences' website at https://ir.castlebiosciences.com/news-events/ir-events. A replay of the webcast will be available following the conclusion of the live broadcast.Castle will also be available for one-on-one investor meetings during the 10th annual L
- INSIDERChief Commercial Officer Juvenal Tobin W sold $51,191 worth of shares (1,730 units at $29.59) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 75,964 units (SEC Form 4)4 - CASTLE BIOSCIENCES INC (0001447362) (Issuer)
CSTL FAQ
7 questionsWhat does Castle Biosciences Inc. do?
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test...Where does CSTL stock trade?
Castle Biosciences Inc. (CSTL) is listed on NASDAQ.What sector and industry is CSTL in?
Castle Biosciences Inc. operates in the Health Care sector, Medical Specialities industry.When did Castle Biosciences Inc. go public?
Castle Biosciences Inc. (CSTL) completed its IPO in 2019.What are analysts saying about CSTL?
Castle Biosciences Inc. has had 6 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $4000.00 price target on 2026-06-25. Recent price targets range from $2500.00 to $4000.00.What companies are similar to CSTL?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare CSTL side-by-side with any of them on Quantisnow.How can I track CSTL on Quantisnow?
Quantisnow aggregates Castle Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CSTL to receive live email and push alerts on every new disclosure.